ArticleVirulence2016
Antimicrobial blue light inactivation of Candida albicans: In vitro and in vivo studies.
Article in Virulence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Efficacy of Curcumin-Mediated Antimicrobial Photodynamic Therapy onInternational journal of molecular sciences · 2024Pooled it
- The potential role of violet-blue light to preventing hospital acquired infections: a systematic review.Frontiers in public health · 2024Pooled it
- Regular home use of dual-light photodynamic therapy as an adjunct to non-surgical periodontal treatment in smokers: a single-center randomized controlled clinical trial.Clinical oral investigations · 2025Trial
- Smartphone-Guided Visible Light Modulation of RSNOs for Antimicrobial Activity via Controlled Nitric Oxide Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Hydralazine potentiates the antiproliferative effect of photodynamic therapy on Candida albicans and Candida parapsilosis in vitro.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Antimicrobial blue light against healthcare-related Candida species: in vitro efficacy and following repeated exposure for 30 days.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- In Vitro Antifungal Efficacy of Blue-Light Photodynamic Therapy with Curcumin and Riboflavin Formulation Activated by 450 nm Diode Laser AgainstPharmaceutics · 2025Article
- Photoinactivation of influenza viruses by modulated indoor daylight spectrum and intensity.Applied and environmental microbiology · 2025Article
- Beyond Resistance: Tolerance and Resilience of Bacteria to Photodynamic and Oxidative Stress.International journal of molecular sciences · 2025Review
- Studying the viability and growth kinetics of vancomycin-resistant Enterococcus faecalis V583 following femtosecond laser irradiation (420-465 nm).Lasers in medical science · 2024Article
- Evaluation of antifungal activity of visible light-activated doped TiOPhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Sensitivity of Xylella fastidiosa subsp. pauca Salento-1 to light at 410 nm.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Red/Orange Autofluorescence in Selected Candida Strains Exposed to 405 nm Laser Light.Dentistry journal · 2024Article
- Fungal photoinactivation doses for UV radiation and visible light-a data collection.AIMS microbiology · 2024Review
- Identification and validation of reference genes for quantitative gene expression analysis under 409 and 415 nm antimicrobial blue light treatment.Frontiers in molecular biosciences · 2024Article
- Innovative Phosphorene Nanoplatform for Light Antimicrobial Therapy.Pharmaceutics · 2023Review
- [Research advances on invasive fungal infections after burns].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Review
- A Novel Technique for Disinfection Treatment of Contaminated Dental Implant Surface Using 0.1% Riboflavin and 445 nm Diode Laser-An In Vitro Study.Bioengineering (Basel, Switzerland) · 2022Article
- Light-activated molecular machines are fast-acting broad-spectrum antibacterials that target the membrane.Science advances · 2022Article
- Photoinactivation of Catalase Sensitizes Candida albicans and Candida auris to ROS-Producing Agents and Immune Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Fungal infections are a common cause of morbidity, mortality and cost in critical care populations. The increasing emergence of antimicrobial resistance necessitates the development of new therapeutic approaches for fungal infections. In the present study, we investigated the effectiveness of an innovative approach, antimicrobial blue light (aBL), for inactivation of Candida albicans in vitro and in infected mouse burns. A bioluminescent strain of C. albicans was used. The susceptibilities to aBL (415 nm) were compared between C. albicans and human keratinocytes. The potential development of aBL resistance by C. albicans was investigated via 10 serial passages of C. albicans on aBL exposure. For the animal study, a mouse model of thermal burn infected with the bioluminescent C. albicans strain was used. aBL was delivered to mouse burns approximately 12 h after fungal inoculation. Bioluminescence imaging was performed to monitor in real time the extent of infection in mice. The results obtained from the studies demonstrated that C. albicans was approximately 42-fold more susceptible to aBL than human keratinocytes. Serial passaging of C. albicans on aBL exposure implied a tendency of reduced aBL susceptibility of C. albicans with increasing numbers of passages; however, no statistically significant difference was observed in the post-aBL survival rate of C. albicans between the first and the last passage (P>0.05). A single exposure of 432 J/cm(2) aBL reduced the fungal burden in infected mouse burns by 1.75-log10 (P=0.015). Taken together, our findings suggest aBL is a potential therapeutic for C. albicans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.